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Prenatal tobacco exposure has been usually assessed using selfreported maternal questionnaire. Difficulties in differentiating passive tobacco exposure from active smoking (among there reluctant to admit active smoking or unconscious of passive exposure) have prompted the use of specific biomarkers to prevent bias in self-reported questionnaires. 3, 4 Nicotine and its main metabolite (cotinine) have been used as biomarkers for second-hand smoke in conventional (blood and urine) and non-conventional matrices (saliva, meconium and hair). 5 Cotinine presents a longer biological half-life than nicotine, and it is considered the best biochemical marker to differentiate between active and passive tobacco exposure. Moreover, the levels of cotinine have been found to be directly related with daily cigarette consumption. 6 We believe that the accurate assessment of fetal exposure to smoking through the objective measure of a biomarker could be of major importance in cohort studies, in which the ultimate goal is monitoring passive exposure to tobacco smoke and the investigation of the effects of prenatal and postnatal environmental exposures to pollutants, including tobacco smoke. Cord serum cotinine appeared to be an adequate biomarker due to its ability to be associated with levels of active smoking, levels of passive maternal exposure to smoking, and to neonatal effects such as birth weight. Cord serum cotinine is able to discriminate active smoking from exposure to environmental tobacco smoke and exposure from non-exposure. Finally, the ease of collection and processing of cord blood advocate for the extension of the use of cord serum cotinine as a biomarker of prenatal exposure to smoking. 2 Cotinine cord blood is the most sensitive and less invasive measure of prenatal second-hand smoke in newborns and usually has a good correlation with self-reported smoking parents. 2, 7, 8 In addition, we did not suggest that umbilical cord tissue would act as a reservoir for cotinine when we discussed the physicochemistry of cotinine and the makeup of the umbilical tissue. The pharmacokinetic flow of cotinine with respect to mom's blood, placenta, umbilical tissue and fetal blood is not fully elucidated. Hence, cotinine, having a longer half-life than nicotine, is still detectable in the tissue and may be indicative of smoke exposure, but not quantitative for amounts of exposure. Cord serum can be used to quantitate the amount of exposure, and when available may be superior. There are times, however, when cord serum is not available, as it was not collected. Our method provides a means to assess tobacco exposure in those cases when the placenta and cord are available but not the serum.
Strength in numbers: a step closer to standardising perinatal care for drug-misusing women and their infants We read with great interest the recent paper by Isemann et al.
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In this retrospective review of 128 neonates the severity of neonatal abstinence syndrome (NAS) was mitigated by reducing maternal methadone dose during pregnancy and encouraging breastfeeding. We fully support these conclusions but believe there to be some shortcomings in the study including failure to document the incidence of NAS in the population studied. We caution against using length of stay as a proxy for NAS severity; these infants typically have complex social backgrounds and often require prolonged hospital stays simply to facilitate discharge planning.
Isemann et al. 1 note that optimal management of NAS has been confounded by inconsistencies in the literature; it is unfortunate that they did not consider our review 2 of 444 mother-infant pairs (by far the largest cohort studied to date), which provides a great deal of clarity. All our mothers were prescribed substitute methadone (median dose 50 mg per day, range 5-150 mg), and at least 80% used additional illicit drugs. 45.5% of infants received pharmacological treatment for NAS. The odds ratio of requiring treatment for NAS was independently related to prescribed maternal methadone dose (rather than associated polydrug misuse) and was halved by breastfeeding.
The main procedural difference between our practice and that in Cincinnati is the use of oral morphine rather than methadone as first-line pharmacotherapy for NAS. We both administer medication every 4 h (despite the considerably longer half-life of methadone) and we both use phenobarbital as a second-line agent with potential for use at home. In our unit, NAS per se is not necessarily an indication for admission to the Neonatal Unit, and infants may receive pharmacological treatment while remaining with their mothers in the postnatal ward.
The authors and their extended clinical team are to be commended on achieving such a high rate of breast milk feeding (60.8%). Although we question the accuracy of reviewing 'nursing flow sheets y to determine the proportion of total intake that was comprised of MBM (maternal breast milk)' unless infants received measured volumes of expressed breast milk rather than suckling, the observed association between maternal breast milk feedings and shorter duration of neonatal methadone treatment complements our own observations and supports encouragement of breastfeeding in this population. Contrary to Isemann et al., 1 we did not observe any cases of rebound withdrawal symptoms amongst the 51 infants in our group who were still breastfeeding at discharge, but we agree wholeheartedly that further studies in this area are warranted. We described almost three times as many preterm infants (90 versus 36) and observed no association between preterm birth and the development of NAS.
To conclude, we are delighted that Isemann's findings are generally consistent with our own and we are optimistic that the growing evidence base will put to rest (finally) the debate over conflicting results of older, smaller studies of NAS. Obstetric and Neonatal teams now have sound data from both sides of the Atlantic to inform guideline development, thus improving
